Peptide
FOXO4-DRI
FOXO4-DRI (Proxofim, D-retro-inverso FOXO4 peptide)
A synthetic senolytic peptide designed to disrupt the FOXO4-p53 interaction inside senescent cells. Aged-mouse data is real. Human trials do not exist. A 2023 Circulation paper flagged pulmonary hypertension risk in animals.
Summary Can FOXO4-DRI safely remove damaged aging cells in people? Show / hide ↓
FOXO4-DRI is an experimental peptide, meaning a short chain of protein building blocks, designed to remove senescent cells, which are old or damaged cells that no longer work normally. In a 2017 study, three doses of 5 mg per kilogram helped aged mice clear these cells and improved hair growth, kidney function, and running distance. However, a 2023 study found that it worsened heart function and increased deaths in mice with pulmonary hypertension, a condition involving high blood pressure in the lung vessels. No human trials have been completed or are in progress, so its safety and benefits for people are unknown.
What this means for you: FOXO4-DRI has promising but animal-only evidence and a serious safety signal in one mouse disease model. There is not enough evidence to use it outside research.
conflicting evidenceFOXO4-DRI is the most cited example of the emerging class of designer senolytic peptides. The idea, developed by Peter de Keizer's group at Erasmus MC in Rotterdam, is that senescent cells survive because a FOXO4-p53 protein complex keeps p53 away from mitochondrial apoptosis machinery. A peptide that mimics the FOXO4 binding site can competitively disrupt that complex and tip senescent cells into programmed death, while leaving healthy cells alone.
The headline result: in a 2017 paper in Cell, de Keizer's group treated aged mice with FOXO4-DRI at 5 mg per kg intraperitoneal, three doses every other day. Old animals cleared senescent cells, regained hair coat density, restored kidney function, and increased treadmill running distance. This was one of the cleanest senolytic effects reported in mice to that point.
The complication came in 2023. A Circulation paper reported that FOXO4-DRI treatment in a mouse model of pulmonary hypertension worsened right-ventricular function and increased mortality. The proposed mechanism: senescent endothelial cells in the pulmonary vasculature were preserving fragile vessel structure, and killing them accelerated failure. This is the first serious safety signal for a senolytic peptide in a specific disease context, and it forced a re-read of the earlier optimism.
No human trial of FOXO4-DRI has been completed. Community dosing protocols vary by a factor of 100, ranging from 300 mcg to 33 mg per dose, with no published rationale for any of these numbers. Quarterly pulse dosing (hit-and-run) is the standard biohacker pattern, borrowed from the mouse protocol.
The p53 tumor surveillance concern deserves its own line. FOXO4-DRI works by freeing p53. In healthy cells with intact DNA damage response, this should be neutral. In cells with pre-cancerous mutations or with impaired p53 function, the effect is unpredictable, and there is no clinical data to define which subgroups face what risk.
Our position: FOXO4-DRI sits at Tier 5, with an active safety-signal footnote. The 2017 Cell paper made the case for the class. The 2023 Circulation paper made the case for extreme caution. Users cycling this peptide are running unmonitored n=1 experiments with a molecule that has not received a single completed human trial.
Further reading
Curated external sources for a deeper dive. External links open in a new tab.